Optional product analytics
With your permission, we use privacy-limited analytics to understand which research journeys work. We do not run advertising trackers or session replay. You can change this choice in Preferences. Read the Privacy Policy.
Sanofi's published Buy conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $104.3B | |
|---|---|---|
| Revenue (ttm) | 55.9B | |
| Net income (ttm) | 4.5B | |
| EPS (ttm) | $1.82 | |
| Shares out | 1.2B | |
| P/E (trailing) | 23.2x | |
| P/E (forward) | 8.4x | |
| Dividend | $2.42 (5.73%) | |
| Volume | 2,730,232 | |
| Beta | 0.28 |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | Trend |
|---|---|---|---|---|---|
| Period | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
| Revenue | $40.56B | $41.62B | $44.29B | $46.72B | +4.8% |
| Gross profit | $28.68B | $28.99B | $31.08B | $33.67B | +5.5% |
| Operating income | $10.40B | $6.89B | $7.40B | $6.80B | -13.2% |
| Net income | $8.37B | $5.40B | $5.56B | $7.81B | -2.3% |
| EPS (diluted) | $2.69 | $2.16 | $2.30 | $3.20 | +6.0% |
| EBITDA | $13.51B | $11.32B | $10.99B | $12.48B | -2.6% |
| R&D | $6.50B | $6.51B | $7.39B | $7.84B | +6.5% |
| SG&A | $8.74B | $9.48B | $9.82B | $10.24B | +5.4% |
Recent company headlines from major financial publishers.
Revenue accelerates beyond the historical 4.82% CAGR toward the 6.12% next-year estimate, driven by successful pipeline commercialization. Operating margins improve past 20%, and the equity partially re-rates toward the peer median.
Growth remains stable, anchored by vaccines and rare diseases. The 12.0x terminal multiple reflects a conservative partial re-rating from the current 8.4x, deliberately constrained below peers due to the rigid 97.7% dividend payout policy.
| Ke ↓ / g → | 1.5% | 2.0% | 2.5% | 3.0% | 3.5% |
|---|---|---|---|---|---|
| 6.3% | $61.9 | $69.2 | $78.4 | $89.5 | $89.5 |
| 7.3% | $51.2 | $56.0 | $61.9 | $69.2 | $78.4 |
| 8.3% | $43.6 | $47.1 | $51.2 | $56.0 | $61.9 |
| 9.3% | $38.0 | $40.6 | $43.6 | $47.1 | $51.2 |
| 10.3% | $33.6 | $35.7 | $38.0 | $40.6 | $43.6 |
Upcoming earnings date and setup when available.
The rating each month's published research edition carried. A rating compares the price at analysis with the Fair value; it is not a record of whether the call was right.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |
